白蛋白-胆红素分级联合血小板预测无需内镜筛查食管静脉曲张的代偿期肝细胞癌患者
本研究旨在探讨肝细胞癌(HCC)患者高危食管静脉曲张(HRV)的患病率与危险因素,并评估白蛋白-胆红素分级联合血小板计数(ALBI-PLT评分)预测代偿期患者无需内镜筛查HRV的价值。研究纳入887例代偿期患者(研究队列,2007年10月至2014年4月)并215例验证队列(2014年5月至2015年12月)。结果显示ALBI-PLT评分2分者HRV发生率2.9%,>2分者21.1%;阴性预测值在研究队列和验证队列分别为97.1%和98.1%;5年累积静脉曲张出血率2分者1.7% vs >2分者9.1%(P=0.007)。
要点
- ALBI-PLT评分2分的代偿期HCC患者HRV发生率仅2.9%,阴性预测值97.1%。
- ALBI-PLT评分>2分的代偿期HCC患者HRV发生率为21.1%。
- ALBI-PLT评分2分者5年累积静脉曲张出血率1.7%,低于>2分者的9.1%(P=0.007)。
核心结论
- 在肝功能代偿的HCC患者中,ALBI-PLT评分2分预测HRV和静脉曲张出血风险极低,因此不推荐对这些患者进行食管静脉曲张内镜筛查。
研究设计与样本
- 研究队列纳入2007年10月至2014年4月的887例代偿期HCC患者,验证队列纳入2014年5月至2015年12月的215例代偿期HCC患者。
- ALBI-PLT评分计算方法为ALBI分级加上血小板计数评分:血小板计数>150,000/mm3计1分,≤150,000/mm3计2分。
主要发现
- 研究队列中,ALBI-PLT评分2分的代偿期HCC患者HRV发生率为2.9%,评分>2分者为21.1%。
- ALBI-PLT评分预测HRV的阴性预测值在研究队列为97.1%,在验证队列为98.1%。
- 对于HCC诊断时未接受内镜筛查的代偿期患者,ALBI-PLT评分2分者5年累积静脉曲张出血率为1.7%,低于评分>2分者的9.1%(P=0.007)。
关键数值与推荐
- ALBI-PLT评分2分对应HRV发生率2.9%(研究队列),阴性预测值97.1%(研究队列)和98.1%(验证队列)。
- ALBI-PLT评分>2分对应HRV发生率21.1%(研究队列)。
- ALBI-PLT评分2分者5年累积静脉曲张出血率1.7%,>2分者9.1%(P=0.007)。
临床怎么用
- 作者认为,对于肝功能代偿的HCC患者,ALBI-PLT评分2分预测HRV和静脉曲张出血风险极低,不推荐进行食管静脉曲张内镜筛查。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUNDS AND AIMS: There is no consensus on screening for high-risk esophageal varices (HRV) in patients with hepatocellular carcinoma (HCC). Here, we aimed to investigate the prevalence and risk factors of HRV in patients with HCC and to assess the combination of albumin-bilirubin grade and platelet count (ALBI-PLT score) for predicting compensated patients who do not need unnecessary endoscopic screening for HRV. METHODS: The ALBI-PLT score was calculated by adding the ALBI grade and points for platelet count (1 point if platelet count >150,000/mm3 and 2 points if ≤150,000/mm3). The predictive value of the ALBI-PLT score for HRV was analyzed in 887 compensated patients enrolled from October 2007 to April 2014 (study cohort). This was validated in 215 compensated patients from May 2014 to December 2015 (validation cohort). RESULTS: In the study cohort, the rates of HRV were 2.9% and 21.1% in compensated HCC patients with an ALBI-PLT score of 2 and >2, respectively. The negative predictive values of the ALBI-PLT score for predicting HRV were 97.1% and 98.1% in the study and validation cohorts, respectively. For compensated patients who did not receive endoscopic screening at the time of HCC diagnosis, the 5-year cumulative variceal hemorrhage rate was lower in patients with an ALBI-PLT score of 2 than in those with an ALBI-PLT score >2 (1.7% vs 9.1%, P = .007). CONCLUSION: In patients with HCC with compensated liver function, an ALBI-PLT score of 2 predicted a very low risk of HRV and variceal hemorrhage; therefore, endoscopic screening for esophageal varices is not recommended for these patients.
引用
- Chen PH, Hsieh WY, Su CW, et al. Combination of albumin-bilirubin grade and platelets to predict a compensated patient with hepatocellular carcinoma who does not require endoscopic screening for esophageal varices. Gastrointest Endosc. 2018. PMID: 29317268. doi:10.1016/j.gie.2017.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。